RT Journal Article SR Electronic T1 Polygenic risk prediction and SNCA haplotype analysis in a Latino Parkinson’s disease cohort JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.11.09.21265082 DO 10.1101/2021.11.09.21265082 A1 Loesch, Douglas A1 Horimoto, Andrea R. V. R. A1 Sarihan, Elif Irem A1 Inca-Martinez, Miguel A1 Mason, Emily A1 Cornejo-Olivas, Mario A1 Torres, Luis A1 Mazzetti, Pilar A1 Cosentino, Carlos A1 Sarapura-Castro, Elison A1 Rivera-Valdivia, Andrea A1 Medina, Angel C. A1 Dieguez, Elena A1 Raggio, Victor A1 Lescano, Andres A1 Tumas, Vitor A1 Borges, Vanderci A1 Ferraz, Henrique B. A1 Rieder, Carlos R. A1 Schumacher-Schuh, Artur A1 Santos-Lobato, Bruno L. A1 Velez-Pardo, Carlos A1 Jimenez-Del-Rio, Marlene A1 Lopera, Francisco A1 Moreno, Sonia A1 Chana-Cuevas, Pedro A1 Fernandez, William A1 Arboleda, Gonzalo A1 Arboleda, Humberto A1 Arboleda-Bustos, Carlos E. A1 Yearout, Dora A1 Zabetian, Cyrus P. A1 International Parkinson Disease Genomics Consortium (IPDGC) A1 Thornton, Timothy A. A1 Mata, Ignacio F. A1 O’Connor, Timothy D. A1 on behalf of the Latin American Research Consortium on the Genetics of Parkinson’s Disease (LARGE-PD) YR 2021 UL http://medrxiv.org/content/early/2021/11/11/2021.11.09.21265082.abstract AB Background Large-scale Parkinson’s disease (PD) genome-wide association studies (GWAS) and meta-analyses have, until recently, only been conducted on subjects with European-ancestry. Consequently, polygenic risk scores (PRS) constructed using PD GWAS data are likely to be less predictive when applied to non-European cohorts.Methods Using GWAS data from Nalls et al. 2019, we constructed a PD PRS for a Latino PD cohort (LARGE-PD) and tested it for association with PD status. We validated the PRS performance through testing the PD PRS in an independent cohort of Latino PD patients and by repeating the PRS analysis in LARGE-PD with the addition of 440 external Peruvian controls. To explore the global distribution of PD PRS, we utilized 1000 Genomes Project (1KGP) and Peruvian Genome Project (PGP) data to estimate PD risk allele frequencies. We also tested SNCA haplotypes for association with PD risk using logistic regression in LARGE-PD and a European-ancestry PD cohort from the International Parkinson Disease Genomics Consortium (IPDGC).Results The GWAS-significant PD PRS had an area under the receiver-operator curve (AUC) of 0.668 (95% CI: 0.640-0.695) and explained 2.2% of the phenotypic variance on the liability scale in LARGE-PD. The inclusion of external Peruvian data as controls mitigated this result, dropping the AUC 0.632 (95% CI: 0.607-0.657). In 1KGP Latinos, we found the PD PRS to exhibit a bias by ancestry. At the SNCA locus, haplotypes differ by ancestry. Ancestry-specific SNCA haplotypes were associated with PD status in both LARGE-PD and the IPDGC cohort (p-value < 0.05). Apart from rs356182, these haplotypes share as little as 14% of their variants.Conclusion The PD PRS has potential for PD risk prediction in Latinos, but variability caused by admixture patterns and bias in the PD PRS calculated using only European-ancestry data limits its utility. The inclusion of diverse subjects can help elucidate PD risk loci and improve risk prediction in non-European cohorts. In the case of the SNCA locus, by leveraging a Latino cohort, we provide orthogonal evidence for rs356182 causality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institute of Neurological Disorders and Stroke under award R01NS112499 (PI: IFM), a Stanley Fahn Junior Faculty Award (PI: IFM) and an International Research Grants Program award from the Parkinson's Foundation (PI: IFM), by a research grant from the American Parkinson's Disease Association (PI: IFM), and with resources and the use of facilities at the Veterans Affairs Puget Sound Health Care System. This project was partially supported by "The Committee for Development and Research" (Comite para el desarrollo y la investigacion-CODI)-Universidad de Antioquia grant #2020-31455 to CV-P and MJ-D-R. TDO was supported by National Human Genome Research Institute of the National Institutes of Health under Award Number R35HG010692. DPL was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number T32HL007698.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by VA Puget Sound IRB, with the project name "LARGE-PD: Latin American Research Consortium of the Genetics of Parkinson's Disease", RDIS number: 0010, MIRB number: 00087. Currently, the study is under Cleveland Clinic IRB: 19-340.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors